A study published next week in the open access journal PLoS Medicine suggests that elderly people with damaged kidneys are at greater risk of cardiovascular disease, such as heart failure and stroke, and other causes of mortality. The findings indicate that greater efforts should be made to encourage elderly people who have impaired kidney function
Full Post: Impaired kidney function raises risk of heart problems in the elderly
Researchers at the Indiana University School of Medicine have identified a potential new target in the war on HIV/AIDS.
The information was published in the Jan. 16 issue of the journal Molecular Cell .
The study revealed that a variant of a protein involved in HIV pathogenesis can suppress production of an HIV protein, known as Nef. Nef is required for the human immunodeficiency virus to develop into AIDS through a series of complex events involving viral elements and cellular proteins. Nef has never been a target for drug treatment in HIV patients.
Johnny J. He, Ph.D., principal author of the research and the director of the Indiana University Center for AIDS Research, said a drug affecting Nef could complement existing therapies to provide protection against the virus.
The current treatment for HIV/AIDS is highly active anti-retroviral therapy (HAART). It is a combination of drugs that target two HIV enzymes - reverse transcriptase (RT) and protease (PR) or RT or PR inhibitors.
Dr. He said another encouraging outcome of the research was the discovery that Nef could be suppressed on the molecular level to prevent it from translating into protein.
“These scientific advances have therapeutic potential to interrupt the progression of the virus into AIDS,” said Dr. He, who also is a professor of microbiology and immunology and medicine.
http://www.iu.edu/
--------------------------------------------------------------------------------------------
Related Posts:
Combination therapies similar to those used for HIV patients may be the best way of treating hepatitis C virus (HCV), say researchers from the University of Leeds. A study of a protein called p7, has revealed that differences in the genetic coding of the protein between virus strains - known as genotypes - alter the
Full Post: Potential new therapy for hepatitis C treatment
The Food and Drug Administration within the U.S. Department of Health and Human Services (HHS) has reached the milestone of the 75th anti-retroviral generic drug approved or tentatively approved as part of President Bush’s Emergency Plan for AIDS Relief (PEPFAR). Marketed by Macleods Pharmaceuticals, Ltd, of Kachigam, Daman, in the Republic of India, the
Full Post: FDA grants tentative approval for 75th generic anti-retroviral drug
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. In a study appearing in the December issue of Nature Medicine , groups of guinea pigs infected with a virus similar to Lassa fever virus recovered from the fatal disease
Full Post: Researchers develop new strategy for broad spectrum anti-viral drugs
A new study led by researchers at Albert Einstein College of Medicine of Yeshiva University has clarified how two major variants of HIV differ in their ability to cause neurologic complications. The finding, published in Journal of Neuroscience, highlights a new target for drugs that could prevent HIV-associated dementia, an incurable and increasingly common complication
Full Post: Potential new target for drugs to prevent HIV-associated dementia
A previously unknown regulatory step during human immunodeficiency (HIV) replication provides a potentially valuable new target for HIV/AIDS therapy, report researchers at the Salk Institute for Biological Studies and the University of Wisconsin, Madison. Their study, published in this week’s early online edition of the Public Library of Science, PLoS Pathogens, describes a new biological
Full Post: Previously unknown regulatory step during HIV replication provides potential new target for HIV/AIDS therapy --------------------------------------------------------------------------------------------
